In 73 children and adults with ataxia-telangiectasia, 12 weeks of levacetylleucine improved SARA ataxia score versus placebo in a phase 3 crossover trial (mean change −1·92 vs −0·14; effect −1·88, p<0·0001), with no treatment-related serious adverse events.
RCTn = 73
Martakis et al. Safety and efficacy of levacetylleucine in ataxia-telangiectasia: a phase 3, randomised, double-blind, placebo-controlled crossover trial